Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells

Prostate

Volumn 67, Issue 10, 2007, Pages 1121-1131

  Morgenroth, Agnieszka ^a   Cartellieri, Marc ^a   Schmitz, Marc ^a   Günes, Serap ^a   Weigle, Bernd ^a,b   Bachmann, Michael ^a   Abken, Hinrich ^c   Rieber, Ernst Peter ^a   Temme, Achim ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Eucodis GmbH   (Austria)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chimeric T cell receptor; Immunotherapy; Prostate carcinoma; PSCA

Indexed keywords

ALPHA PROSTATE STEM CELL ANTIGEN; CD3 ANTIGEN; CD3 ANTIGEN ZETA; PROSTATE STEM CELL ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL STRAIN HEK293; CHIMERA; CONTROLLED STUDY; CROSS LINKING; CYTOTOXIC T LYMPHOCYTE; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; CELL LINE, TUMOR; CHIMERA; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; JURKAT CELLS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 34250839415     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20608     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Bertz J, Giersiepen K, Haberland J, Hentschel S, Katsch P, Katalinic R, Ziegler H, Stegmaier C. Krebs in Deutschland, 5 edn.: Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. und das RKI; 2006.
3. Coleman MP, Babb P, Sloggett A, Quinn M, De SB. Socioeconomic inequalities in cancer survival in England and Wales. Cancer 2001;91:208-216.
4. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol 1998;160:1220-1229.
5. Tannock IF, de WR, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
6. Blattman JN, Greenberg PD. Cancer immunotherapy: A treat-ment for the masses. Science 2004;305:200-205.
7. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-357.
8. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004;101 (Suppl 2):14639-14645.
9. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-129.
10. Eshhar Z, Bach N, Fitzer-Attas CJ, Gross G, Lustgarten J, Waks T, Schindler DG. The T-body approach: Potential for cancer immunotherapy. Springer Semin Immunopathol 1996;18:199-209.
11. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993;90:720-724.
12. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995;55:3369-3373.
13. Hombach A, Schlimper C, Sievers E, Frank S, Schild HH, Sauerbruch T, Schmidt-Wolf IG, Abken H. A recombinant anti-CEA immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells. Gut 2005;55(8):1156-1164.
14. Dall P, Herrmann I, Durst B, Stoff-Khalili MA, Bauerschmitz G, Hanstein B, Niederacher D. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells. Cancer Immunol Immunother 2005;54(1):51-60.
15. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Riviere I, Larson SM, Koutcher JA, Sadelain M. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 2005;65(19):9080-9088.
16. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. 1979 [classical article]. J Urol 2002;167:1226-1230.
17. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227-230.
18. Vihko P, Virkkunen P, Hentru P, Roiko K, Solin T, Huhtala ML. Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett 1988;236:275-281.
19. Weigle B, Fuessel S, Ebner R, Temme A, Schmitz M, Schwind S, Kiessling A, Rieger MA, Meye A, Bachmann M, Wirth MP, Rieber EP. D-GPCR: A novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate. Biochem Biophys Res Commun 2004;322:239-249.
20. Weigle B, Kiessling A, Ebner R, Fuessel S, Temme A, Meye A, Schmitz M, Rieger MA, Ockert D, Wirth MP, Rieber EP. D-PCa-2: A novel transcript highly overexpressed in human prostate and prostate cancer. Int J Cancer 2004;109:882-892.
21. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998;95:1735-1740.
22. Antica M, Wu L, Scollay R. Stem cell antigen 2 expression in adult and developing mice. Immunol Lett 1997;55:47-51.
23. Classon BJ, Coverdale L. Mouse stem cell antigen Sca-2 is a member of the Ly-6 family of cell surface proteins. Proc Natl Acad Sci U S A 1994;91:5296-5300.
24. Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 2005;11:2591-2596.
25. Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004;171:1117-1121.
26. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19:1288-1296.
27. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2005.
28. Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, Lutz RJ, Frantz G, Hillan K, Peale F, Tobin P, Eberhard D, Rubin MA, Lasky LA, Koeppen H. Prostate stem cell antigen as therapy target: Tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002;62:2546-2553.
29. Amara N, Palapattu GS, Schrage M, Gu Z, Thomas GV, Dorey F, Said J, Reiter RE. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 2001;61:4660-4665.
30. Argani P, Rosty C, Reiter RE, Wilentz RE, Murugesan SR, Leach SD, Ryu B, Skinner HG, Goggins M, Jaffee EM, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Discovery of new markers of cancer through serial analysis of gene expression: Prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001;61:4320-4324.
31. Elsamman EM, Fukumori T, Tanimoto S, Nakanishi R, Takahashi M, Toida K, Kanayama HO. The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: A quantitative reverse transcriptase-polymerase chain reaction analysis. BJU Int 2006;98:668-673.
32. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, Abken H. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. J Immunother 1999;22:473-480.
33. Wang Z, Raifu M, Howard M, Smith L, Hansen D, Goldsby R, Ratner D. Universal PCR amplification of mouse immunoglobulin gene variable regions: The design of degenerate primers and an assessment of the effect of DNA polymerase 3′ to 5′ exonuclease activity. J Immunol Methods 2000;233:167-177.
34. Temme A, Rieger M, Reber F, Lindemann D, Weigle B, Diestelkoetter-Bachert P, Ehninger G, Tatsuka M, Terada Y, Rieber EP. Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell. Mol Biol Cell 2003;14:78-92.
35. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995;23:628-633.
36. Kaufmann Y, Berke G, Eshhar Z. Cytotoxic T lymphocyte hybridomas that mediate specific tumor-cell lysis in vitro. Proc Natl Acad Sci U S A 1981;78:2502-2506.
37. Temme A, Morgenroth A, Schmitz M, Weigle B, Rohayem J, Lindemann D, Fussel M, Ehninger G, Rieber EP. Efficient transduction and long-term retroviral expression of the melanoma-associated tumor antigen tyrosinase in CD34(+) cord blood-derived dendritic cells. Gene Ther 2002;9:1551-1560.
38. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-6115.
39. Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, Adamzik I, Kabelitz D, Dreger P, Schmitz N, Heiser A. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003;170:5391-5397.
40. Tsuboi K, Saijo K, Ishikawa E, Tsurushima H, Takano S, Morishita Y, Ohno T. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res 2003;9:3294-3302.
41. Hombach A, Muche JM, Gerken M, Gellrich S, Heuser C, Pohl C, Sterry W, Abken H. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells. Gene Ther 2001;8:891-895.
42. Wang J, Press OW, Lindgren CG, Greenberg P, Riddell S, Qian X, Laugen C, Raubitschek A, Forman SJ, Jensen MC. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther 2004;9:577-586.
43. Gyobu H, Tsuji T, Suzuki Y, Ohkuri T, Chamoto K, Kuroki M, Miyoshi H, Kawarada Y, Katoh H, Takeshima T, Nishimura T. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res 2004;64:1490-1495.
44. Kershaw MH, Teng MW, Smyth MJ, Darcy PK. Supernatural T cells: Genetic modification of T cells for cancer therapy. Nat Rev Immunol 2005;5:928-940.
45. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: Current and future diagnostic markers. Clin Cancer Res 2004;10:3943-3953.
46. Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 1991;64:891-901.
47. Geiger TL, Leitenberg D, Flavell RA. The TCR zeta-chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes. J Immunol 1999;162:5931-5939.
48. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002;20:70-75.
49. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006;66:10995-11004.